Downloads: 153

Files in This Item:
File Description SizeFormat 
journal.pone.0145394.pdf611.79 kBAdobe PDFView/Open
Title: Aberrant DNA methylation is associated with a poor outcome in Juvenile myelomonocytic leukemia
Authors: Sakaguchi, Hirotoshi
Muramatsu, Hideki
Okuno, Yusuke
Makishima, Hideki  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-5983-8578 (unconfirmed)
Xu, Yinyan
Furukawa-Hibi, Yoko
Wang, Xinan
Narita, Atsushi
Yoshida, Kenichi
Shiraishi, Yuichi
Doisaki, Sayoko
Yoshida, Nao
Hama, Asahito
Takahashi, Yoshiyuki
Yamada, Kiyofumi
Miyano, Satoru
Ogawa, Seishi  kyouindb  KAKEN_id
Maciejewski, Jaroslaw P.
Kojima, Seiji
Author's alias: 牧島, 秀樹
吉田, 健一
小川, 誠司
Issue Date: 31-Dec-2015
Publisher: Public Library of Science
Journal title: PLOS ONE
Volume: 10
Issue: 12
Thesis number: e0145394
Abstract: Juvenile myelomonocytic leukemia (JMML), an overlap of myelodysplastic/myeloproliferative neoplasm, is an intractable pediatric myeloid neoplasm. Epigenetic regulation of transcription, particularly by CpG methylation, plays an important role in tumor progression, mainly by repressing tumor-suppressor genes. To clarify the clinical importance of aberrant DNA methylation, we studied the hypermethylation status of 16 target genes in the genomes of 92 patients with JMML by bisulfite conversion and the pryosequencing technique. Among 16 candidate genes, BMP4, CALCA, CDKN2A, and RARB exhibited significant hypermethylation in 72% (67/92) of patients. Based on the number of hypermethylated genes, patients were stratified into three cohorts based on an aberrant methylation score (AMS) of 0, 1-2, or 3-4. In the AMS 0 cohort, the 5-year overall survival (OS) and transplantation-free survival (TFS) were good (69% and 76%, respectively). In the AMS 1-2 cohort, the 5-year OS was comparable to that in the AMS 0 cohort (68%), whereas TFS was poor (6%). In the AMS 3-4 cohort, 5-year OS and TFS were markedly low (8% and 0%, respectively). Epigenetic analysis provides helpful information for clinicians to select treatment strategies for patients with JMML. For patients with AMS 3-4 in whom hematopoietic stem cell transplantation does not improve the prognosis, alternative therapies, including DNA methyltransferase inhibitors and new molecular-targeting agents, should be established as treatment options.
Rights: © 2015 Sakaguchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
URI: http://hdl.handle.net/2433/210540
DOI(Published Version): 10.1371/journal.pone.0145394
PubMed ID: 26720758
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.